Depomed Inc

Depomed — Investor Presentation (January 2018)

20 slides from Depomed's investor presentation, Jan 8, 2018

  1. Slide 1: Forward Looking Statements Safe Harbor

    Forward Looking Statements “Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("Act"). The forward-looking statements are inten

  2. Slide 2: Principles Guiding the Way We Do Business

    Principles Guiding the Way We Do Business PUTTING PRODUCTIVITY Aimed at Improving Effectiveness Across the Business PROFITABILITY in Line with the Patient First Our Peer Group 3 January 2018

  3. Slide 3: A Clear Strategy for Growth

    A Clear Strategy for Growth Executing on a Three Pillar Growth Strategy MAINTAIN a Strong/Profitable NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business Collegium Transaction December 2017 90 Rep Salesforce Operational October 2017 Cosyntropin Depot Transaction Announ

  4. Slide 4: Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA Franchise

    Collegium Deal Supports Maintaining a Strong/Profitable NUCYNTA® Franchise At closing, Collegium Pharmaceutical will obtain the rights to commercialize NUCYNTA® • – – – Depomed will retain ownership of the NDAs and be responsible for NUCYNTA® product supply Depomed will maintain responsibility for p

  5. Slide 5: Industrial Logic is Clear and Compelling

    Industrial Logic is Clear and Compelling: Financially, Strategically and Patient-Focused 6 January 2018 Depomed Collegium Financially Immediately Accretive Improves Absolute EBIDTA Strategically Collegium as a Leader in Pain and Depomed Ability to Focus on Neurology/ Orphan Drugs Allows Significant

  6. Slide 6: Collegium: Ideal Partner to Take NUCYNTA to the Next Level

    Collegium: Ideal Partner to Take NUCYNTA® to the Next Level • Recognized as an emerging leader in pain management and committed to building a leading pain company Xtampza® ER is the fastest growing Extended Release branded opioid Strong home office, commercial and managed care infrastructures Salesf

  7. Slide 7: Headquarters Restructuring and Relocation Aligns with New Business Model

    Headquarters Restructuring and Relocation Aligns with New Business Model • Headquarters Relocation in 2018: Evaluating Mid-West Coast Sites Provides Improved Access to Pharmaceutical Talent Current Footprint: and East • • Depomed Now Leaner, Nimbler, Financially Stronger – – 60,000 square feet housi

  8. Slide 8: Potential for EBIDTA Improvement

    Potential for EBIDTA Improvement Assumed NUCYNTA Net Sales* *For illustrative purposes only Guidance to be Provided in 2018 9 January 2018 $220mm $240mm $260mm Potential EBIDTA Enhancement Resulting from Collegium Transaction $50 $37 $24 Royalty Payment Change to Grünenthal ($3.2) - $1.2 Net EBIDTA

  9. Slide 9: Grow Our Neurology and Pain Businesses

    Grow Our Neurology and Pain Businesses • September marked the completed relaunch of our Neurology salesforce with 90 representatives • Provides proper support to highly-promotionally sensitive products and CAMBIA ® Gralise® GROW October: Increased levels of Gralise® starter packs seen – • • Creates

  10. Slide 10: Build A New Specialty Business

    Build A New Specialty Business • • • Establishment of a New Specialty Products Business Unit Mark Booth as General Manager brings 30+ years of biopharma experience Objective is to build a portfolio of specialty/orphan drugs addressing the unmet needs of the patient, physician and payors Provides a p

  11. Slide 11: Transformational Transaction Creates New Specialty Business

    Transformational Transaction Creates New Specialty Business Depomed/ Slán Medicinal Holdings Limited • Acquisition of Cosyntropin (Synthetic ACTH Depo) provides a late-stage, high-value product Depomed is the exclusive licensee for United States Current U.S. market is led by H.P. Acthar® Gel (Natura

  12. Slide 12: Gralise: Differentiated within Highly Promotionally Sensitive Market

    Gralise®: Differentiated within the 71MM Annual Prescription Highly Promotionally Sensitive Market Indication • Management of post-herpetic neuralgia • • 2016 net sales of $88 million 3Q 2017 net sales of $21 million Performance Clinical Differentiation • • Only once-daily formulation of gabapentin

  13. Slide 13: Cambia: Differentiated within Highly Promotionally Sensitive Market

    Cambia®: Differentiated within the 15MM Annual Prescription Highly Promotionally Sensitive Market Indication • Acute migraine attacks in adults • • 2016 net sales of $31 million 3Q 2017 net sales of $8 million Performance • Only single-agent in therapeutic class for acute migraine Clinical Different

  14. Slide 14: Zipsor: Differentiated within Highly Promotionally Sensitive Market

    Zipsor®: Differentiated within the 11MM Annual Prescription Highly Promotionally Sensitive Market Indication • Mild to moderate acute pain in adults • • 2016 net sales of $28 million 3Q 2017 net sales of $3.2 million Performance Clinical Differentiation • • Only prescription NSAID in gel cap form Un

  15. Slide 15: Milestones Driving Growth in 2018 and Beyond

    Milestones Driving Growth in 2018 and Beyond • • NUCYNTA® Commercialization Agreement: Close Agreement with Collegium Pharmaceutical Synthetic Cosyntropin (Synthetic ACTH Depot): Commenced Investigational New Drug (IND) Trial in Infantile Spasms Purdue Litigation: Pre-Trial Conference to Set Trial D

  16. Slide 16: Third Quarter 2017 Revenue Overview

    Third Quarter 2017 Revenue Overview 3Q 2017 total GAAP revenues of $95.4 million 3Q 2017 net sales of $58.7 million versus $63.9 million in 2Q 2017 3Q 2017 net sales of $21.1 million versus $18.1 million in 2Q 2017 3Q 2017 net sales of $8.2 million versus $8.5 million in 2Q 2017 3Q 2017 net sales of

  17. Slide 17: Third Quarter 2017 Overview

    Third Quarter 2017 Overview Decreased approximately two days from end of Q2 2017 Approximately 18% of revenue; down slightly from the second quarter $48.9 million $46.8 million $1.8 million $1.7 million $30.1 million versus $28.3 million in Q2 2017 18 January 2018 Non-GAAP EBIDTA Non-GAAP R&D GAAP R

  18. Slide 18: Full-Year Guidance

    Full-Year Guidance* * Depomed Third Quarter 2017 Press Release dated November 7, 2017 Impact of Hurricanes Irma and Maria on the NUCYNTA® ER Supply are in line with guidance 19 January 2018 Updated Guidance Prior Guidance Total Revenue (GAAP) $375 to $380 million $395 to $410 million Total Revenue (

  19. Slide 19: Our Commitment to Shareholders

    Our Commitment to Shareholders Exec on a Clear Strategy of Leverage Opportunities Drive Superior Profitability Maintain a Strong NUCYNTA Franchise, Committed to Putting the Gro Our Neurology and Pain Businesses and Build Patient First a Ne Specialty Bus 20 January 2018

  20. Slide 20: Execute on a Clear Strategy

    Execute on a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Committed to Grow Our Neurology and Putting the Pain Businesses and Build Patient First a New Specialty Business voor 3\KDEPOMED

Depomed — Investor Presentation (January 2018) on 6ix